News & Events

Rebecca Li speaks at Duke-Margolis Center for Health Policy event

Vivli Executive Director, Rebecca Li, spoke at the Duke-Margolis Center for Health Policy event entitled “Data Capture to Measure, Track, and Improve Antibiotic Use” on March 2nd. She took part in the panel discussion for ‘Policy Approaches to Improve Data Capture for Antibiotic Use’ which discussed the need for the expansion of programs to capture antimicrobial resistance surveillance data, and the barriers stakeholders encounter in gathering evidence for novel antibiotics.

Vivli team authors new publication in GARDP’s REVIVE newsletter

Vivli Executive Director Rebecca Li and Antimicrobial Development Consultant Patricia Bradford recently authored a Viewpoint article entitled “Access to industry antimicrobial resistance (AMR) susceptibility surveillance data” in the GARDP REVIVE newsletter. This paper aims to raise awareness of the availability of high-quality AMR susceptibility data collected from surveillance programs by the pharmaceutical industry. These data are freely available and can be requested through the AMR Register by researchers wishing to advance the fight against antimicrobial resistance.

Vivli Executive Director Dr. Rebecca Li Speaking at the PACCARB September Public Meeting (Innovation Spotlight)

Vivli’s Executive Director, Dr. Rebecca Li, spoke at The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) Public Meeting on September 13th for the Innovation Spotlight, on the topic “AMR Register – An Innovative platform for sharing industry surveillance data”. Dr. Li spoke alongside other companies with innovations in antimicrobial resistance. View Dr. Li’s slides here.

This meeting of PACCARB aimed to “identify key issues and critical policy gaps through a series of facilitated discussions examining a hypothetical large-scale disease outbreak scenario based on historic examples and estimates of future AMR outbreaks.”

Further information about the meeting can be found here.

Media Coverage and Social Media Update

Media Roundup:

Social Media:

Pablo-David Rojas on Twitter: “Here a valuable and powerful tool, data-driven and very useful to tackle #AntimicrobialResistance”

Nadine Hillock on Twitter: ”Fantastic initiative! 👏👏 AMR data sharing platform for researchers to access resistance data held by industry”

Damiano de Felice on Twitter: “Kudos to @Wellcome_AMR and @VivliCenter.It is great to see that the #AMRregister has become a reality”

CIDRAP-ASP on Twitter: “New interview! @cvdall speaks with Dr @rebeccali2006 about the launch of @VivliCenter’s AMR Register, which allows access to raw antibiotic susceptibility data collected by pharmaceutical and biotech companies”

AMR Action Fund on Twitter: “Great Q&A btwn @cvdall and @VivliCenter’s Rebecca Li about the newly launched AMR Register, which is supported by our portfolio co @VenatorxPharma and several of our investors incl @pfizer, @GSK, @JNJGlobalHealth, @Merck, @SHIONOGI_JP https://cidrap.umn.e”

Pfizer Medical on Twitter: “We’re pleased to lead the way as a founding contributor of antimicrobial surveillance raw data to @VivliCenter AMR Register, enabling key decision makers access to trends in resistance #AMR”

Merck on Twitter: “We are proud to include our SMART surveillance program in the new #AMR Register from @VivliCenter, helping preserve antibiotics for future generations. Learn more:”

Francesca on Twitter: “Wow it is fantastic to see this becoming reality and with so many contributing companies @Wellcome_AMR @VivliCenter”

Venatorx Pharmaceuticals on Twitter: “Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance. Log on and explore the Register today!! @VivliCenter @GSK @pfizer @Merck @JNJGlobalHealth @SHIONOGI_JP @ParatekPharma @ViatrisInc

Karla Childers on Twitter: “Congratulations to @VivliCenter for the launch of the AMR register! It was an honor to be part of the event today.”

CIDRAP-ASP on Twitter: “Today, @VivliCenter launched the Antimicrobial Resistance Register, which makes it possible for biopharmaceutical companies to share susceptibility data on infection-causing pathogens for the first time ever in one online platform”

Venatorx on LinkedIn: “ATTENTION: Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance”

Jeevan John on LinkedIn: “Insight has partnered again with nonprofit Vivli in its launch of an AMR data-sharing platform to help clinical researchers tackle the problem.”

Health Europa on LinkedIn: “Leading pharmaceutical companies have joined forces to share surveillance data on antibiotic-resistant bacteria to tackle the global threat of antimicrobial resistance (AMR).”

Robert Kane on LinkedIn: “The World Health Organization cautions that people’s growing resistance to antibiotics puts us at risk to future pandemics. Insight’s effort to help nonprofit data-sharing organization Vivli launch a new clinical research platform unites the work of the world’s sharpest researchers looking to solve this issue.”


Foundation Briefing on Industry AMR Surveillance: Data for Action


Join us for a Foundation Briefing on Industry AMR Surveillance: Data for Action.

See our inspiring line-up in the agenda and speaker biographies.

It will be a virtual event on:

September 30, 2021
9:00-12:00 ET / 14:00-17:00 BST / 22:00-1:00 JST

The meeting will be a focus on industry antimicrobial resistance surveillance as we wish to raise awareness of the value of AMR surveillance data.

There will be contributions from AMR experts in academia, industry and funders and Q&A with participants. We do hope you will be able to join us. We will also introduce the AMR Register that will be launched next year and is currently funded by the Wellcome Trust.

Secure your place:
Register today

Vivli awarded contract to improve access to Antimicrobial Resistance Surveillance data

Vivli is pleased to announce that following on from the Wellcome Trust-Open Data Institute (ODI) AMR pilot, Wellcome has awarded a contract to Vivli which aims to improve the access and research use of antimicrobial resistance (AMR) surveillance data.

The Wellcome-ODI pilot project focused on gathering and openly publishing data on industry-sponsored human antimicrobial surveillance programs. Vivli will develop a plan to foster increased research using the surveillance data in collaboration with a Steering Committee of industry data contributors. The Steering Committee, as well as a Scientific Advisory Board, will help steward the project forward.

“Our hope is that the research project will further advance understanding in the medical community, global organizations such as the United Nations and the World Health Organisation, and wider society,” said Rebecca LI, Vivli Executive Director and lead for the project. “We would like to thank the Open Data Institute and all companies and stakeholders who took part in this initiative.”

Insight Enterprises, Vivli’s long-time partner, will undertake the technical development of the platform linked to this grant.